Developmental Research Program
Developmental Research Program
批准号:
10237884
负责人:
Maurizio Scaltriti
金额:
$6.71万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-08-13 至 2025-07-31
关键词:
AddressAdvocateAttentionBRCA1 geneBRCA2 geneBenchmarkingBiological MarkersBreast Cancer PatientBreast Cancer PreventionBreast Cancer TreatmentBudgetsCHEK2 geneChromosomal InstabilityChronologyClinicalCommittee MembersCommunitiesDNA RepairDataDefectDevelopmentDiagnosisDiseaseDoctor of PhilosophyEnsureEtiologyFertilizationFosteringFundingFutureGenerationsGenesGeneticGenomic InstabilityGenomicsGoalsGrantHigh PrevalenceHospitalsInvestigator-Initiated ResearchKnowledgeLeadershipMalignant NeoplasmsMemorial Sloan-Kettering Cancer CenterMentorsMolecularMonitorMutagenesisNew YorkPathway interactionsPatient CarePatientsPatternPeer ReviewPilot ProjectsPlatinumPlayPresbyterian ChurchPreventionProcessResearchResearch PersonnelResearch Project GrantsResourcesRoleSaltsSeedsSelection CriteriaTimeTranslational ResearchUniversitiesVotinganticancer researcharmbasecareercatalystcommunity centergenomic signaturehigh riskhomologous recombinationhormone receptor-positivehormone therapyinhibitor/antagonistinnovationmalignant breast neoplasmmedical schoolsoptimal treatmentspredictive markerprogramsspecific biomarkerssuccesstargeted agenttherapy resistanttranslational cancer researchtranslational research programtreatment responsetriple-negative invasive breast carcinomatumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Abstract/ Summary (DRP)
Breast cancers frequently harbor specific patterns of homologous recombination (HR) DNA repair defects (HRD)
and/or specific patterns of genetic instability, namely chromosomal instability (CIN) and APOBEC mutagenesis.
These alterations are present in a substantial proportion of breast cancers and they are enriched in metastatic
disease. Biomarkers to identify these patients reliably and to define the optimal treatments for these patients are
sorely needed. The Developmental Research Program (DRP) will play an important role in fostering translational
research endeavors focusing on breast cancer, in particular research addressing specific patterns of DNA repair
defects and/or genetic instability and their molecular basis. We will use DRP funding supplemented by a strong
commitment of institutional funds to support innovative projects by new and established investigators, which are
critical to the generation of new ideas in the diagnosis and treatment of this large subset of breast cancers. Our
goal is to establish mechanisms for rapid funding of important new directions to accelerate progress towards the
translational research goals of our SPORE. We identified a credible portfolio of promising developmental
research projects, which will be competing for support once the program is established. We will request pilot
project proposals with translational potential from clinical and basic investigators within the larger MSKCC
community, including Rockefeller University, New York-Presbyterian Hospital and Weill Cornell Medical College
of Cornell University. We will then select the most promising new projects for support after rigorous peer review
by the Leadership Committee, the Internal Advisory Board and the Patient Advocates. The opinion of external
reviewers will be solicited as needed. Pilot projects will be funded for 1 year, but investigators may apply for
additional funding through this same competitive process the next year. Every year the Advisory and Leadership
Committee members will meet to review each research project, core, career enhancement project and
developmental pilot project. Committee members will be asked to assess whether any developmental project
has progressed sufficiently and shown enough translational potential, so as to eclipse one of the full SPORE
Research Projects. The committee members will then vote and decide whether any developmental project should
be advanced to full project status. If so, the budgets will be appropriately adjusted and sent for approval with the
TRP of the NCI.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Developmental Research Program
-
批准号:10478018
-
项目类别:
-
资助金额:$8.66万
-
财政年份:2020
-
负责人:Maurizio Scaltriti
-
依托单位:
Developmental Research Program
-
批准号:10704113
-
项目类别:
-
资助金额:$6.71万
-
财政年份:2020
-
负责人:Maurizio Scaltriti
-
依托单位:
The possible role of the novel Akt 3 R247C mutation in opposing to anti-HER2 ther
-
批准号:8747894
-
项目类别:
-
资助金额:$8.76万
-
财政年份:2014
-
负责人:Maurizio Scaltriti
-
依托单位:
海外基金